High Cost Drugs
This page contains guidance issued by the GMMMG High Cost Drugs Subgroup. If you are an NHS healthcare professional working within the GM region and wish to submit information for consideration by the group please contact the professional secretary of the group via email
| Document Title | Issue Date | Review Date | Status |
|---|---|---|---|
| Tariff-excluded drugs and devices | |||
| Enabled Blueteq List | Sep 2021 | ||
| Free of charge (FOC) medicines schemes | Jan 2020 | Jan 2022 | |
| Position statement: Funding of high cost drugs when patients transition from children or adolescent services to adult services | Oct 2017 | To be reviewed if national or GMMMG guidance changes | |
| Sequential use of high cost drugs statement | Jun 2022 | ||
| Commissioning framework for biologic medicines: defining best value | Jun 2018 | To be reviewed if national or GMMMG guidance changes | |
| High Cost NHS Payment Scheme-excluded Drugs Gainshare Policy | Oct 2024 | To be reviewed if national or GMMMG guidance changes | |
| Position statement for using biologic therapies to treat adult patients with Juvenile Idiopathic Arthritis (JIA) | Oct 2017 | To be reviewed if national or GMMMG guidance changes | |
| Botulinum toxin guidance | Jan 2020 | Jan 2022 | |
| Teriparatide biosimilar uptake recommendation | Nov 2019 | To be reviewed if national or GMMMG guidance changes |